Interleukin 6 Versus Lactic Acid in Septic Shock
Interleukin 6 Versus Lactic Acid for Early Prediction and Prognosis in Septic Shock
The aim of this study is to compare between IL 6 versus lactate level for early prediction and prognosis over the first two days or 48 hours of ICU stay in patients with septic shock.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:• Adult patients aged ≥18 years.
- Both sexes.
- Admitted to the ICU with a diagnosis of sepsis according to Sepsis-3 criteria.
- Presence of life-threatening organ dysfunction indicated by an increase in SOFA score of ≥ 2 points from baseline.
Exclusion Criteria:• Pregnancy.
- Known terminal illness with expected survival rate < 24 hours.
- Cardiopulmonary resuscitation (CPR) within 24 hours before ICU admission.
- Chronic kidney disease requiring analysis.
- LAC next ≥ LAC peak; Patients' medical records are insufficient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Assessment of IL-6
The patients will have blood drawn on day 1 and day 2 of their stay in the ICU. The samples will be processed immediately; |
they will be centrifuged at 3500 rpm for 10 min at 4 ◦C and frozen at -80 ◦C.. |
|
Experimental: Biochemical Assessment
Fasting blood samples will be drawn from ICU patients by venepuncture after the hemodynamic stabilization phase of admission and after 2 days of being in the ICU to measure renal function (ions and creatinine), liver function (bilirubin), nutritional parameters (folic acid, B12 and copper), hematimetric [hemoglobin, leukocytes, platelets, INR and activated partial thromboplastin time (APTT)] and inflammatory parameters [lactic acid, fibrinogen, lactate dehydrogenase (LDH)]. |
Fasting blood samples will be drawn from ICU patients by venepuncture after the hemodynamic stabilization phase of admission and after 2 days of being in the ICU to measure renal function (ions and creatinine), liver function (bilirubin), nutritional parameters (folic acid, B12 and copper), hematimetric [hemoglobin, leukocytes, platelets, INR and activated partial thromboplastin time (APTT)] and inflammatory parameters [lactic acid, fibrinogen, lactate dehydrogenase (LDH)]. PCR and PCT will be performed by the hospital laboratory using standard techniques. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
• Correlation between IL-6 and lactic acid.
Time Frame: 90 days
|
90 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- asyut icu 40
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.